Using Multiple Anchor- and Distribution-Based Estimates to Evaluate Clinically Meaningful Change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) Instrument  by Yost, Kathleen J. et al.
Volume 8 • Number 2 • 2005
V A L U E  I N  H E A L T H
© ISPOR 1098-3015/05/117 117–127 117
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR82117127Original ArticleClinically Meaningful Change on the FACT-BRMYost et al.
Address correspondence to: Kathleen J. Yost, Center on
Outcomes, Research and Education (CORE), Evanston
Northwestern Healthcare, 1001 University Place, Suite 100,
Evanston, IL 60201, USA. E-mail: kyost@enh.org
Portions of this article were presented at the Assessing Clin-
ical Signiﬁcance for Quality of Life Measures in Oncology
Research: State-of-the-Science Quality of Life Symposium,
Rochester, MN, April 2002, and at the Drug Information
Association 9th Annual Symposium for Quality of Life
Evaluation, Hilton Head Island, SC, USA, March 2002.
Using Multiple Anchor- and Distribution-Based Estimates to 
Evaluate Clinically Meaningful Change on the Functional 
Assessment of Cancer Therapy-Biologic Response Modifiers 
(FACT-BRM) Instrument
Kathleen J. Yost, PhD,1 Mark V. Sorensen, PhD,2 Elizabeth A. Hahn, MA,1 G. Alastair Glendenning, MSc,3 
Ari Gnanasakthy, MBA, MSc,4 David Cella, PhD1
1Center on Outcomes, Research and Education (CORE), Evanston, IL, USA; 2Department of Anthropology, University of North 
Carolina, Chapel Hill, NC, USA; 3Novartis AG, Horsham, Sussex, UK; 4Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
ABSTRACT
Objective: The interpretation of health-related quality of
life (HRQL) data from clinical trials can be enhanced by
understanding the degree of change in HRQL scores that
is considered meaningful. Our objectives were to combine
distribution-based and two anchor-based approaches to
identify minimally important differences (MIDs) for the
27-item Trial Outcome Index (TOI), the seven-item Social
Well-Being (SWB) subscale, and the six-item Emotional
Well-being (EWB) subscale from the Functional Assess-
ment of Cancer Therapy-Biological Response Modiﬁers
(FACT-BRM) instrument.
Methods: Distribution-based  MIDs  were  based  on
the standard error of measurement. Anchor-based
approaches utilized patient-reported global rating of
change (GRC) and change in physician-reported perform-
ance status rating (PSR). Correlations and weighted
kappa statistics were used to assess association and agree-
ment between the two anchors. FACT-BRM changes were
evaluated for three time periods: baseline to month 1,
month 2 to month 3, and month 5 to month 6.
Results: Association between GRC and change in PSR
was poor. Correlation between the anchors and HRQL
change scores was largest at month 1 and decreased
through month 6. Combining results from all approaches,
the MIDs identiﬁed were 5–8 points for the TOI, 2 points
for the SWB subscale, and 2–3 points for the EWB
subscale.
Conclusions: We combined patient-reported estimates,
physician-reported estimates, and distribution-based esti-
mates to derive MIDs for HRQL outcomes from the
FACT-BRM. These results will enable interpretation of
treatment group effects in a clinical trial setting, and they
can be used to estimate sample size or power when
designing future studies.
Keywords: clinical signiﬁcance, clinical trials, health-
related quality of life, minimally important difference.
Introduction
Health-related quality of life (HRQL) is a multidi-
mensional construct that refers to the extent to
which one’s usual or expected physical, emotional,
and social well-being are affected by a medical con-
dition or its treatment [1]. By its very nature, HRQL
is subjective. Interest in evaluating HRQL outcomes
in clinical trials continues to increase with greater
emphasis on measuring patient-reported outcomes,
evaluating what is an important change from the
patient’s perspective [2], and including patient-
reported outcomes as primary end points in clinical
trials [3]. Providing HRQL information to patients
becomes increasingly important for making treat-
ment decisions that may affect length of survival,
functional status, or pain and symptom manage-
ment [4,5].
A number of issues need to be considered when
including HRQL measures in clinical trials. Use of
rigorously validated HRQL instruments is critical,
because it is a need to ensure that results are mean-
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ingful to  both  clinicians  and  patients.  Logistical
and methodological issues to consider include the
timing of assessments, selection of relevant HRQL
domains, sample size estimation, and speciﬁcation
of hypotheses to be tested. Deﬁning the meaning-
fulness of change in HRQL scores is critical for
determining appropriate sample sizes, interpreting
treatment group results, and understanding change
over time. Determination of a clinically meaningful
change is challenging because HRQL measures lack
a “gold standard” against which to quantify mean-
ingful change.
Meaningful change in HRQL can be assessed
using distribution- or anchor-based methods [6,7].
Distribution-based measures rely on the statistical
distributions of HRQL data, and include effect size
measures [8–10], the standard error of measure-
ment (SEM) [11,12], the responsiveness index [13]
and the reliable change index [14]. Anchor-based
approaches involve comparing changes in HRQL
scores to patient-reported assessments of change
over time [15,16] or to clinically relevant measures
such as performance status or response to treatment
[17,18]. Jaeschke and colleagues [19] developed an
anchor-based approach using a global rating of
change (GRC) to estimate what they describe as the
minimal clinically important difference (MCID) in
HRQL change scores, deﬁned as “the smallest dif-
ference in score in the domain of interest which
patients perceive as beneﬁcial and which would
mandate, in the absence of troublesome side effects
and excessive cost, a change in the patient’s man-
agement [19].” The terminology for meaningful
change is varied [20] and lacks consensus [7,21].
We employ the more commonly used term of min-
imally important difference (MID) herein.
The GRC is a retrospective assessment of per-
ceived change; that is, patients are asked to think
back to a previous time point and state whether
they have experienced any change in a domain of
health and/or HRQL from that time point to the
present. Response options typically range from
“very much worse” through “about the same” to
“very much better.” We and others have applied
the Jaeschke et al. method to the analysis of HRQL
[15,19], including the analyses of change in HRQL
scores in a clinical trial [16]. Serial, or prospective
anchors, have also been used to identify MIDs
[18,22,23]. For a prospective anchor, a patient is
rated with respect to the clinical anchor at two
time points; for example, once at baseline before
commencing treatment and again 1 month later.
The change in the anchor over these two time
points can be used to assess the clinical meaning-
fulness of change in HRQL scores over the same
time.
The Functional Assessment of Cancer Therapy—
General (FACT-G) [24] is a 27-item instrument
developed to measure HRQL in cancer patients.
The FACT-G measures the general domains of
HRQL, including physical well-being (PWB, seven
items), functional well-being (FWB, seven items),
social/family well-being (SWB, seven items) and
emotional well-being (EWB, six items). A common
practice is to supplement a general HRQL instru-
ment with additional items that capture informa-
tion speciﬁc to a particular disease or treatment
[25]. This approach was taken when developing the
FACT-Biological Response Modiﬁers (FACT-BRM)
instrument, which supplements the FACT-G with
13 disease- and treatment-speciﬁc items addressing
concerns commonly experienced by cancer patients
undergoing treatment with biological response
modiﬁers [26–28]. These 13 items form two sub-
scales, physical BRM and emotional/cognitive
BRM, or they can be combined into a single sub-
scale. The Trial Outcome Index (TOI) is a 27-item
summary measure of physical function and well-
being, and it is derived by summing the PWB, FWB,
and BRM subscale scores. TOI scales have been
derived for other instruments in the Functional
Assessment of Chronic Illness Therapy (FACIT)
measurement system and have proven to be valua-
ble summary measures in clinical trials [18,22,29].
The Cronbach’s alpha for the 27-item TOI from the
FACT-BRM is very high (0.91–0.93) [27], which
supports combining these items to create a single
scale. More information about the FACT-BRM and
other FACIT instruments is available at http://
www.facit.org
The purpose of the present study was to identify
MIDs for the 27-item TOI, the seven-item SWB sub-
scale, and the six-item EWB subscale. We illustrate
an approach for identifying MIDs that combines
distribution-based estimates and two types of
anchor-based estimates.
Methods
Participants were newly diagnosed patients with
chronic phase chronic myelogenous leukemia par-
ticipating in the International Randomized Inter-
feron versus ST1571 (IRIS) Study, a prospective
multicenter open-label Phase III randomized study
[27,30]. A total of 1106 patients were randomized
to either oral imatinib (STI571) 400 mg daily or
subcutaneous interferon-alpha (IFNa) plus low-
dose Ara-C (IFNa + LDAC). A substudy was con-
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ducted during  the  ﬁrst  6 months  of  treatment  in
a subset of 200 patients in the United States. The
principal investigator of the substudy (A.G.)
designed a GRC questionnaire, described in detail
below, which was completed by 175 (87.5%) of
these patients.
HRQL Assessment
HRQL was measured monthly during the ﬁrst
6 months of the trial using the FACT-BRM [27,28].
The GRC substudy was designed to identify an
MID for the TOI, the primary HRQL end point in
the IRIS trial. We also wanted to identify MIDs for
the SWB and EWB subscales, which were consid-
ered secondary HRQL end points. Scoring of the
FACT-BRM was performed as described in the
FACIT manual [26].
Patient-Reported GRC
A self-administered GRC questionnaire was devel-
oped based on the methods established by Jaeschke
et al. [19]. The meaning of each subscale (PWB,
SWB, EWB, FWB, BRM) as well as overall HRQL
was brieﬂy described and then patients rated the
degree of change they had experienced in each of
these domains since the last time they completed the
FACT-BRM. Thus, there was a GRC rating for each
of the subscales (GRCPWB, GRCSWB, GRCEWB,
GRCFWB, GRCBRM) and overall HRQL (GRCTotal).
Patients reported change on a ﬁve-point scale rang-
ing from 1 = “a lot better” to 5 = “a lot worse.”
Patients provided these ratings at months 1, 3, and
6. The GRC measured at month 1 reﬂected patients’
perceived change from baseline to month 1,
whereas GRC measured at month 3 reﬂected per-
ceived change  from  month  2,  and  GRC  at month
6 reﬂected perceived change from month 5. To
evaluate a GRC rating corresponding to the TOI
(GRCTOI), the mean of the GRCPWB, GRCFWB, and
GRCBRM was computed. Mean scores were then
rounded to the nearest integer to correspond to the
ratings on the GRC questionnaire. Because of small
sample sizes in some of the GRC categories, patients
were further classiﬁed into three categories by com-
bining the “a lot better” and “somewhat better”
categories into one category (“better”), and by com-
bining the “somewhat worse” and “a lot worse”
categories into a single category (“worse”).
Physician-Reported Performance Status Rating (PSR)
The Eastern Cooperative Oncology Group (ECOG)
PSR is an assessment of current functional status
often used in clinical trials. PSR grades range from
0 to 4, where 0 = fully ambulatory without symp-
toms, 1 = fully ambulatory with symptoms,
2 = requiring bed rest less than half of the waking
day, 3 = requiring bed rest more than half of the
waking day, and 4 = bedridden. Only patients with
PSR grades of 0, 1, or 2 were eligible for the IRIS
clinical trial. Physician-determined PSR was
recorded at each monthly visit; thus, PSR can be
considered a prospective anchor. We computed
change in PSR for three time intervals: month 1
minus baseline, month 3 minus month 2, and
month 6 minus month 5. Patients whose PSR
declined by 1 or more points were classiﬁed as
“worse,” patients whose PSR did not change were
classiﬁed as “same,” and patients who improved by
1 or more points were classiﬁed as “better.”
Statistical Analysis
Descriptive statistics. Internal consistency reliabil-
ity of the FACT-BRM was assessed using
Cronbach’s coefﬁcient alpha. To evaluate the
concordance between patient-reported and physi-
cian-reported estimates of change, Spearman rank
correlation coefﬁcients were computed for PSR
change scores and GRC ratings, both deﬁned in
three categories of “worse,” “same,” and “better.”
Because PSR change and GRCTOI are both predom-
inantly measures of change in physical functioning,
we expected the correlation between PSR change
and GRCTOI to be larger than correlations between
PSR change and either GRCSWB or GRCEWB.
Weighted kappa statistics were also used to assess
agreement between PSR change and GRC deﬁned in
three categories.
Distribution-based approach. Meaningful change
was deﬁned as one SEM and was computed at base-
line using the following formula: 
where s is the standard deviation of the subscale
and rxx is the reliability of the subscale, measured
here as Cronbach’s alpha [11]. Although other mul-
tiples of the SEM, including 1.96 SEM [14] and
2.77 SEM [31], have been used to identify mean-
ingful change, we chose 1.0 SEM because this value
has been speciﬁcally linked to the MID in HRQL
[11,12]. Effect sizes were computed by dividing the
SEM by the standard deviation of the baseline
score.
Anchor-based approach. Two anchors were used to
assess meaningful change in HRQL: 1) patient-
reported GRC; and 2) physician-reported PSR.
Changes in HRQL scores were computed within
each GRC category (worse, same, better). Effect
sizes for change in HRQL scores at month 1 were
SEM = -s 1 rxx
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computed by dividing the mean change score from
baseline to month 1 by the standard deviation of the
baseline score. The HRQL mean change score from
month 2 to month 3 was divided by the month 2
standard deviation and the mean change score from
month 5 to month 6 was divided by the month 5
standard deviation to derive effect sizes for those
assessments. Patients were also grouped according
to PSR change category, and mean change in HRQL
scores and effect sizes were computed within each
category as described above. An effect size of 0.2
was considered small, 0.5 was moderate and 0.8
was large [8]. FACT-BRM change scores should
increase monotonically in line with moving from
the categories “worse” to “better” on the GRC and
PSR change. For example, changes in TOI scores for
the “worse” GRCTOI category should be negative,
changes in the “about the same” GRCTOI category
should be near zero, and changes for the “better”
GRCTOI category should be positive.
Crosby et al. [7] suggest that the usefulness of an
anchor depends on the correlation between the
HRQL change score and the anchor. We used sta-
tistical signiﬁcance (P < 0.05) of a Spearman corre-
lation coefﬁcient to assess the usefulness of anchors.
In this study, if the correlation between the anchor
and the change in HRQL score was not positive and
not statistically signiﬁcant, the anchor was consid-
ered inappropriate for assessing change in HRQL,
and the HRQL change score was not included in the
determination of the MID. We anticipated the cor-
relations between the GRC and HRQL change to be
moderate to large. Because the PSR change is a
measure of change in physical functioning, we
anticipated the correlation with change in TOI
scores to be moderate to large and the correlations
with change in SWB and EWB scores to be small.
Clinically meaningful change. No single method
for identifying MIDs is sufﬁcient; therefore, it has
been recommended that multiple strategies be used
simultaneously [32,33]. Furthermore, because
MIDs may vary slightly across patient groups,
reporting a range of plausible MIDs rather than a
single number has been recommended [32,33].
Mean change scores with large effect sizes (> 0.8)
[8] were not included in the determination of the
MID because, while clinically meaningful, these
changes are too large to be considered MIDs. We
summarized the anchor-based MID estimates using
medians and interquartile ranges to facilitate iden-
tifying a range of plausible MIDs. The interquartile
range has been recommended for providing reason-
able bounds around the MID because it is robust to
possibly asymmetric distributions of MID estimates
[34].
Meaningful declines in FACT-G scores based on
the GRC anchor were larger on average than mean-
ingful improvements [15]. This trend was also
observed for the FACT-Colorectal based on two
patient-reported anchors: general health and bowel
function [23]. Meaningful declines in FACT scores
based on change in physician- and patient-reported
PSR, however, have tended to be smaller on average
than meaningful improvements [18,35]. Thus, the
asymmetric nature of meaningful change in HRQL
scores may depend on the anchor used. Others have
observed a trend in HRQL change scores suggesting
declines are larger than improvements [36,37], but
a recent review of MID research concluded there
was insufﬁcient evidence to support the assertion
that MIDs for worsening states were larger than
those for improving states [20]. We computed MIDs
for all patients combined, but we also present plau-
sible MIDs separately for patients who decline and
improve as secondary or exploratory ﬁndings.
Based on results from an expert panel [38], the
smallest clinically important difference of a scale
should be larger than its intrinsic variability
(deﬁned here as one SEM). Therefore, we ensured
that the ranges of MIDs identiﬁed included the next
possible HRQL score larger than the SEM. To
enhance interpretation of MIDs across scales with
different numbers of items, we described the MIDs
in terms of average change per item. For example,
an MID of 2 points for a seven-item scale corre-
sponds to a change of 2/7 = 0.29 points per item.
Results
Baseline demographic and clinical characteristics of
the substudy population are presented in Table 1,
and baseline descriptive statistics for the FACT-
BRM scores are presented in Table 2. The charac-
teristics of patients in this substudy were similar to
those for all patients enrolled in the IRIS trial [39].
The mean SWB score for this substudy was higher
than the general US population norm, but the mean
EWB score was lower than the norm [40]. There are
currently no normative data for the TOI from the
FACT-BRM instrument.
Correlations between change in PSR and
GRCTOI, GRCSWB,  and  GRCEWB  were  highest  at
month  1 (Table 3). These correlations decreased
and remained fairly consistent at months 3 and 6.
As expected, the correlations between PSR change
and GRCTOI were larger than the correlations
between PSR change and GRCSWB or GRCEWB at all
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time points. Overall agreement between PSR change
and GRC as measured by a weighted kappa statistic
was poor (Table 3). Agreement was better at the
month 1 assessment than at months 3 and 6, and it
was better for PSR change versus GRCTOI than for
PSR change versus GRCSWB or GRCEWB.
Distribution-Based Analysis
The estimates of one SEM were 4.2 points for the
TOI, 1.9 points for the SWB, and 2.2 points for the
EWB (Table 2). Effect sizes associated with these
SEMs were 0.25 for the TOI, 0.48 for the SWB, and
0.50 for the EWB, which were considered small to
moderate [8].
Anchor-Based Analyses
Mean changes in TOI scores are presented in
Table 4. TOI change scores were asymmetric in that
the absolute values of the mean change scores for
the “worse” category were markedly larger than
changes in the “better” category for all but PSR
change at months 3 and 6. TOI change scores in the
“about the same” group were near zero for the
month 3 and month 6 assessments, as expected.
Table 1 Baseline demographic and clinical characteristics
US patients 
N = 175
Age (year)
Median (range) 52 (18–70)
≥60, no. (%) 28 (18)
Sex, no. (%)
Male 107 (61.1)
ECOG performance status rating, no. (%)
0 = Fully ambulatory without symptoms 136 (78.2)
1 = Fully ambulatory with symptoms 35 (20.1)
2 = less than 50% bed rest during waking day 3 (1.7)
Interval from diagnosis (month)
Median (range) 1.7 (0–7.3)
Sokal risk group, no. (%)
Low 49 (28.0)
Intermediate 44 (25.1)
High 13 (7.4)
Unknown 69 (39.4)
Hasford risk group, no (%)
Low 61 (34.9)
Intermediate 30 (17.1)
High 21 (12.0)
Unknown 63 (36.0)
Table 2 Baseline HRQL scores
FACT scale/subscale Range Mean (SD)
Cronbach’s 
alpha SEM
US general  
population norm  
mean (SD) [40]
Trial Outcome Index (TOI, 27-items) 22–108 84.9 (16.5) 0.94 4.2 NA
Social Well-Being (SWB, 7-items) 4–28 24.3 (4.0) 0.77 1.9 19.1 (6.8)
Emotional Well-Being (EWB, 6-items) 4–24 17.8 (4.4) 0.76 2.2 19.9 (4.8)
SEM, one standard error of  measurement; NA, not available.
Table 3 Spearman correlations and weighted kappa statis-
tics for PSR change versus GRCTOI, GRCSWB, GRCEWB
GRCTOI GRCSWB GRCEWB
Correlation
Month 1 0.37 0.24 0.23
Month 3 0.25 0.13 0.09
Month 6 0.25 0.11 0.09
Kappa statistic
Month 1 0.28 0.13 0.15
Month 3 0.12 0.00 0.00
Month 6 0.18 0.12 0.05
PSR change, change in physician-reported performance status rating; GRCEWB,
patient-reported global rating of  change in emotional well-being; GRCSWB,
patient-reported global rating of  change in social well-being; GRCTOI, patient-
reported global rating of  change in physical functioning and well-being.
Table 4 Change in TOI scores by patient-reported GRC rat-
ings and by change in physician-reported PSR
n
TOI change
score 
mean (SD)
Overall
SD*
Effect
size†
GRCTOI groups
Month 1
Worse 57 -28.2 (17.1)‡ -1.76
About the same 61 -5.6 (12.3) 16.0 -0.35
Better 43 5.7 (14.6) 0.31
Month 3
Worse 23 -8.9 (11.1) -0.42
About the same 71 0.1 (10.7) 21.1 0.00
Better 52 6.9 (13.5) 0.33
Month 6
Worse 18 -8.8 (9.0) -0.43
About the same 80 0.9 (7.9) 20.3 0.04
Better 53 3.6 (12.2) 0.18
PSR change groups
Month 1
Worse 39 -27.5 (21.3)‡ -1.71
About the same 103 -6.3 (16.1) 16.1 -0.39
Better 15 4.3 (15.9) 0.27
Month 3
Worse 22 -5.5 (10.9) -0.26
About the same 108 0.7 (10.7) 21.0 0.03
Better 16 9.9 (21.4) 0.47
Month 6
Worse 11 -7.2 (8.6) -0.36
About the same 117 0.9 (8.9) 20.2 0.05
Better 16 6.2 (15.2) 0.31
*SD at baseline, month 2 or month 5.
†Effect size calculated as the change score divided by the overall SD.
‡This estimate of  change was not considered in the determination of  the MID
because the effect size is greater than 0.8.
GRCTOI, patient-reported global rating of  change in physical functioning and well-
being; PSR, physician-reported performance status rating. See text for descrip-
tion of  change; TOI, trial outcomes index.
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Nevertheless, patients classiﬁed as “about the
same” according to their GRCTOI or PSR change at
month 1 experienced declines in their TOI scores of
-5.6 for GRCTOI and -6.3 for PSR change, which
correspond  to  small  to  moderate  effect  sizes  of
-0.35 and -0.39, respectively.
The  results  of  the  anchor-based  analysis  for
the SWB subscale are in Table 5. Absolute change
scores for patients classiﬁed as “worse” based on
GRCSWB tended to be larger than change scores for
patients classiﬁed as “better”; whereas changes for
declines versus improvements based on PSR change
were essentially equivalent. SWB change scores
were similar for the “about the same” and “better”
categories of GRCSWB at both the month 3 and 6
assessments. This absence of a monotonic increase
in SWB change scores across categories of GRCSWB
at months 3 and 6 indicates that self-reported GRC-
SWB did not reﬂect change in the SWB subscale at
those assessments. SWB was slightly more respon-
sive to PSR change as indicated by negative change
scores in the “worse” category and positive change
scores in the “better” category. The GRCSWB anchor
suffered from small sample sizes in the “worse” cat-
egory at all assessments.
Table 6 contains the results of the anchor-based
analysis for EWB. For this subscale, change scores
for declines were essentially the same magnitude as
those for improvements based on the GRCEWB at
months 1 and 3 and based on PSR change at months
6. Improvements were larger than declines for the
GRCEWB at month 6 and for PSR change at months
1 and 3. There was evidence of a lack of monotonic
increase in EWB change score across the anchors for
the GRCEWB at month 6 and the PSR change at
month 3.
Clinically Meaningful Change
Correlations between FACT-BRM scores and the
anchors are summarized in Table 7. The correla-
tions between change in TOI and both anchors
(GRCTOI and change in PSR) were statistically
signiﬁcant at all assessments; therefore, they were
considered appropriate anchors for measuring
Table 5 Change in SWB scores by patient-reported GRC
ratings and by change in physician-reported PSR
n
SWB change
score
mean (SD)
Overall
SD*
Effect
size†
GRCSWB groups
Month 1
Worse 13 -3.8 (4.7)‡ -0.96
About the Same 99 -1.4 (2.9) 3.9 -0.35
Better 47 0.4 (4.9) 0.10
Month 3
Worse 8 -2.8 (4.3)§ -0.64
About the Same 97 -0.03 (3.0) 4.4 0.00
Better 45 -0.06 (2.7)§ 0.02
Month 6
Worse 8 -1.6 (3.2)§ -0.38
About the Same 92 -0.1 (3.1) 4.3 -0.02
Better 45 -0.03 (2.3)§ 0.00
PSR change groups
Month 1
Worse 40 -2.2 (3.6) -0.56
About the Same 104 -1.0 (3.1) 3.9 -0.26
Better 15 2.4 (7.1) -0.62
Month 3
Worse 22 -0.3 (1.7)§ -0.07
About the Same 112 -0.4 (3.1) 4.6 -0.09
Better 16 0.2 (2.3)§ 0.04
Month 6
Worse 11 -1.6 (3.2) -0.33
About the Same 118 -0.2 (2.8) 4.9 -0.04
Better 16 1.4 (3.0) 0.29
*SD at baseline, month 2 or month 5.
†Effect size calculated as the change score divided by the overall SD.
‡This estimate of  change was not considered in the determination of  the MID
because the effect size is greater than 0.8.
§This estimate of  change was not considered in the determination of  the MID
because the SWB change scores were not signiﬁcantly correlated with the
anchor.
GRCSWB, patient-reported global rating of  change in social well-being; PSR: phy-
sician-reported performance status rating. See text for description of  change;
SWB, Social Well-Being subscale.
Table 6 Change in EWB scores by patient-reported GRC
ratings and by change in physician-reported PSR
n
EWB change
score
mean (SD)
Overall
SD*
Effect 
size†
GRCEWB groups
Month 1
Worse 28 -2.1 (5.1) -0.49
About the same 76 0.8 (3.5) 4.3 0.19
Better 60 1.9 (3.8) 0.45
Month 3
Worse 19 -1.1 (3.1) -0.27
About the same 82 -0.4 (3.0) 4.1 -0.10
Better 48 0.7 (2.8) 0.12
Month 6
Worse 18 -0.2 (3.9)‡ -0.05
About the same 75 -0.1 (2.3) 3.9 -0.03
Better 58 0.7 (3.2)‡ 0.18
PSR change groups
Month 1
Worse 39 -0.6 (4.7) -0.07
About the same 105 0.9 (3.8) 4.4 -0.10
Better 15 2.5 (3.7) 0.26
Month 3
Worse 22 -0.3 (2.3)‡ -0.07
About the same 111 -0.4 (3.0) 4.2 -0.10
Better 16 1.1 (2.8)‡ 0.26
Month 6
Worse 11 -1.7 (3.6) -0.38
About the same 118 0.3 (2.4) 4.5 0.07
Better 16 1.6 (4.1) 0.35
*SD at baseline, month 2 or month 5.
†Effect size calculated as the change score divided by the overall SD.
‡This estimate of  change was not considered in the determination of  the MID
because the EWB change scores were not signiﬁcantly correlated with the
anchor.
EWB, emotional well-being subscale; GRCEWB, patient-reported global rating of
change in emotional well-being; PSR: physician-reported performance status rat-
ing. See text for description of  change.
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change in TOI. Mean changes in the “worse” cate-
gory at the month 1 assessment were -28.2 points
for the GRC (effect size -1.76) and -27.5 points for
the PSR change (effect size -1.71; see Table 4).
While these changes are clinically meaningful, they
are too large to be considered a minimal criterion
for assessing meaningful change; thus, these values
were not included in the determination of an MID
for the TOI scale. The remaining absolute anchor-
based change scores ranged from 3.6 to 9.9 points
(Table 4), with a median of 6.6 and an interquartile
range of 5.6–8.4. The distribution-based estimate
(i.e., SEM) was 4.2 points (Table 2). Based on these
estimates, we recommend that changes in TOI
scores between 5 and 8 points be considered mini-
mally clinically important. The lower end of this
range is larger than the SEM, which meets the rec-
ommendation that the MID should be larger than
the inherent variability of the scale [38]. Evaluating
estimates separately for decliners and improvers
suggests MIDs of 8 points for decliners and 6 points
for improvers.
The correlations between change in SWB scores
and GRCSWB were not statistically signiﬁcant at
months 3 and 6, and for PSR change, correlations
were not statistically signiﬁcant at month 3
(Table 7), indicating that these anchors were not
suitable for assessing clinically meaningful change
in the SWB subscale at those times. The mean
month 1 change score in the “worse” category of
GRCSWB was -3.8 and had an effect size of -0.96,
which exceeds our effect size criterion of 0.8 for
identifying minimally important changes. There-
fore, this estimate was not included in the deter-
mination of the MID. Absolute values of the
remaining estimates that were considered ranged
from 0.4 to 2.4 with a median of 1.6 and an inter-
quartile range of 1.4–2.2. The distribution-based
estimate (SEM) is 1.9. Combining the anchor- and
distribution-based results suggests that 2 points is a
plausible MID for SWB subscale scores. There was
inconsistent evidence that SWB change scores in the
“worse” category were larger than in the “better”
category; therefore, MIDs were not evaluated sepa-
rately for declines versus improvements.
The correlation between EWB change scores and
GRCEWB was not statistically signiﬁcant at month 6,
and it was not signiﬁcant between EWB change
scores and PSR change at month 3 (Table 7); thus,
results from these assessments were not considered
appropriate for assessing change in EWB. The
anchor-based MID estimates ranged in absolute
value from 0.6 to 2.5 points with a median of 1.7
and an interquartile range of 1.0–2.0 (see Table 6).
The distribution-based estimate was 2.2 points
(Table 2). The distribution- and anchor-based
estimates cluster around 2 points. Nevertheless,
because the MID range should include the next
score larger than the SEM, our recommended range
of the MID for the EWB subscale is 2–3 points. The
data in Table 6 do not support establishing separate
MIDs for declines versus improvements.
Discussion
We combined distribution-based and two anchor-
based methods to identify the magnitude of a
change in three FACT-BRM end points that could
be considered minimally clinically meaningful.
Recommended MIDs were 5–8 points for the TOI
(0.19–0.30 points per item), 2 points for the SWB
(0.29 points per item), and 2–3 points for the EWB
(0.33–0.50 points per item). The magnitudes of the
MIDs differ because the scales and subscales are
comprised of different numbers of items with dif-
ferent score  ranges  and  different  distributional
and psychometric properties. Although we also
explored the possibility of separate MIDs for the
Table 7 Spearman rank correlations between FACT-BRM
scores and GRC or PSR change
FACT-BRM
scale/
subscale
Anchor (assessment 
period)
Correlations 
Pre* Post† Change‡
TOI GRCTOI (month 1) 0.00§ 0.59 0.68
GRCTOI (month 3) 0.28 0.54 0.39
GRCTOI (month 6) 0.21 0.33 0.24
SWB GRCSWB (month 1) 0.01§ 0.23 0.23
GRCSWB (month 3) 0.17 0.21 0.11§
GRCSWB (month 6) 0.32 0.29 0.09§
EWB GRCEWB (month 1) 0.18 0.45 0.33
GRCEWB (month 3) 0.18 0.29 0.22
GRCEWB (month 6) 0.25 0.36 0.08§
TOI PSR Change (month 1) -0.06§ 0.35 0.48
PSR Change (month 3) 0.02§ 0.18 0.25
PSR Change (month 6) 0.08§ 0.19 0.25
SWB PSR Change (month 1) -0.11§ 0.09§ 0.26
PSR Change (month 3) -0.04§ -0.02§ 0.05§
PSR Change (month 6) 0.03§ 0.13§ 0.22
EWB PSR Change (month 1) -0.03§ 0.15§ 0.19
PSR Change (month 3) -0.04§ 0.02§ 0.13§
PSR Change (month 6) -0.02§ 0.11§ 0.21
*Pre, correlation between anchor and HRQL score measured at Baseline, month
2, or month 5.
†Post, correlation between anchor and HRQL score measured at month 1,
month 3, or month 6.
‡Change, correlation between anchor and HRQL change score.
§Not statistically signiﬁcant. All other P < 0.05.
EWB, emotional well-being subscale; FACT-BRM, Functional Assessment of
Cancer Therapy-Biological Response Modiﬁers; GRC, patient-reported global
rating of  change; PSR change, change in physician-reported performance status
rating. See text for description of  change; SWB, social/family well-being sub-
scale; TOI, trial outcomes index.
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TOI  for  declines  (8  points)  and  for  improvements
(6 points), TOI declines were not consistently and
markedly larger than improvements at all assess-
ments evaluated  in  this  study.  Thus,  at  this  time
we recommend that the MID range based on all
patients combined (i.e., 5–8 points) be used to inter-
pret TOI scores.
Effect sizes for 91% of the TOI estimates, 78%
of the SWB estimates, and 50% of the EWB esti-
mates considered in the determination of MIDs
were between 0.20 and 0.50, which are interpreted
as small to medium effects [8]. Therefore, we are
conﬁdent that the recommended MIDs do, in fact,
approximate the minimum change score one would
consider meaningful in the selected FACT-BRM end
points.
There is growing evidence that MIDs for FACIT
scales and subscales are fairly stable across patient
populations. The recommended MID for the 27-
item TOI scale ranged from 5–8 points, which is
0.19–0.30 points per item. This is very consistent
with ﬁndings from previous research on MIDs for
TOI scales from other FACIT instruments such as
the FACT-Lung [22], FACT-Breast [18], and FACT-
Colorectal [23], for which MIDs for TOIs consist-
ently ranged from 0.19–0.29 points per item [23].
MIDs of 2–3 points for the seven-item PWB and
FWB subscales have been previously reported [15],
which correspond to a range of 0.29–0.43 points
per item. MIDs for cancer-speciﬁc subscales of
FACIT instruments range from 0.22–0.43 points
per item [23]. Our ﬁndings in the present study for
the SWB (0.29 points per item) and EWB (0.33–
0.50 points per item) are consistent with these pre-
vious reports. Based on these ﬁndings, we are con-
ﬁdent that the MIDs for TOI, SWB, and EWB
identiﬁed  in  this  clinical  trial  are  appropriate
for interpreting HRQL data from other patient
samples.
We identiﬁed ranges of MIDs for the TOI and
EWB, as recommended [32,33]. The data in this
study did not support a range of estimates for the
SWB subscale; the anchor-based estimates clustered
around 2 points and the distribution-based estimate
was 1.9. Although SWB change scores were signif-
icantly correlated with GRC at month 1 and with
PSR at months 1 and 3, the magnitudes of these cor-
relations were between 0.22 and 0.26, which are
considered small to moderate [8]. It is possible that
using anchors that are weakly correlated with SWB
underestimated the MID. Additional research is
needed to identify a range of plausible MIDs for the
SWB subscale using anchors that are clinically and
subjectively meaningful to physicians and patients,
as well as strongly correlated (r > 0.3) to SWB
change scores.
The TOI was the primary HRQL end point of the
IRIS trial. The lower end of the MID range for the
TOI (i.e., 5 points) was prespeciﬁed for use in inter-
preting treatment group differences. It was con-
cluded that TOI scores in the imatinib arm were
higher (i.e., better physical function and well-being)
than in the IFNa + LDAC arm, and that the differ-
ence was both statistically signiﬁcant and clinically
meaningful [39]. Furthermore, knowing the MID
for the TOI allowed individual patients in the IRIS
trial to be classiﬁed based on changes in their TOI
scores. Hahn et al. classiﬁed patients into three
categories: clinically relevant improvement (TOI
increased 5 or more points from baseline), clinically
relevant decline (TOI decreased 5 or more points
from baseline), and no change. Clinically relevant
declines in TOI were experienced by 52% to 73%
of patients in the IFNa + LDAC arm compared
with only 22% to 29% of patients in the imatinib
arm. Clinically relevant improvements in TOI were
experienced in 9% to 25% for IFNa + LDAC com-
pared with 29% to 43% for imatinib [39]. HRQL
results presented in this manner can easily be under-
stood by both clinicians and patients. Another use
of MIDs is for estimating sample size or power for
a future study. For example, investigators can deter-
mine the number of subjects needed to detect an
HRQL score difference equal to the MID or larger.
We used two types of anchors: the GRC, which
was a retrospective, patient-reported assessment of
change, and change in PSR, which was a prospec-
tive, physician-reported measure. One or both of
these properties (i.e., retrospective vs. prospective,
patient-reported vs. physician-reported) may be
responsible for the poor agreement between GRC
and PSR change (Table 3). Nevertheless, strong
agreement between PSR change and GRCSWB or
GRCEWB was not expected because PSR is a measure
of change in physical functioning, whereas GRCSWB
and GRCEWB are measures of change in social and
emotional well-being respectively.
Using correlations between HRQL scores and
anchors  to  assess  the  usefulness  of  anchors  for
an MID analysis has been suggested [7] and imple-
mented [23]. We considered only those HRQL
change scores that were statistically signiﬁcantly
related to the anchors. Had we failed to implement
this criterion, the MIDs might have been underesti-
mated. Because correlations between GRC and
HRQL change scores were largest at the month 1
assessment and declined thereafter, the most suita-
ble time to administer the GRC in this trial was at
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month 1, which measured perceived change from
baseline. Our general recommendation is that a
GRC should be administered at a time during a
clinical trial when patients are expected to experi-
ence sufﬁcient change in their health and HRQL.
Thus, this ﬁnding is speciﬁc to this clinical trial and
is not necessarily generalizable to other clinical tri-
als. For example, in another clinical trial there may
be a delayed response to therapy, and patients may
experience little or no change in their HRQL from
baseline to month 1, yet changes from month 5 to
month 6 may be dramatic. In such an example,
GRC administered at month 1 may not provide
useful data for assessing clinically meaningful
change.
Our study is not without limitations. Guyatt
et al. [41] contend that if a transition rating, such as
the GRC, were perfectly valid, it would have corre-
lations with the pre- and post-HRQL scores of
equal magnitude and opposite sign. We did not
observe this pattern with the GRC data in this
study. Correlations between GRCTOI and TOI pre
scores (i.e., baseline, month 2 or month 5) were
small but positive and correlations between GRCTOI
and TOI post scores (i.e., months 1, 3, or 6) were
larger and positive, indicating that patients’ retro-
spective assessment of change may be overly inﬂu-
enced by their current health state, a potential
problem with transition ratings that has been
reported elsewhere [41]. Similar patterns for the
pre- and post correlation coefﬁcients were observed
for the SWB and EWB subscales. These ﬁndings
suggest that GRC may not have been the most sen-
sitive measure of change at all assessment periods
evaluated in this study.
We used a 5-point GRC scale, which we further
collapsed into 3 categories of change. Others have
used 7-point [16] or 15-point [15,41] GRC scales.
Nevertheless, 7 or 15 categories of change may be
too many to provide useful data for estimating the
MID without collapsing categories. Sample sizes
were lower than desired for some of the anchor-
based assessments. We attempted to mitigate this
problem by combining the “much worse” and
“worse” categories and by combining the “much
better” and “better” categories. This has a potential
consequence of possibly increasing the magnitude
of change scores in the combined categories, which
could have led to overestimation of some MIDs.
Nevertheless, our results for recommended MID
ranges based on GRC or PSR change represented by
ﬁve categories (data not shown) versus three cate-
gories were the same. Finally, our ﬁndings may be
inﬂuenced by response shift over time [42] or recall
bias associated with individual perceptions of
change over the course of treatment.
We utilized an approach for identifying MIDs
that combined distribution-based estimates and
both patient- and physician-reported anchor-based
estimates. We reﬁned the anchor-based approach by
using correlation coefﬁcients to assess the appropri-
ateness of  the  anchors  to  identify  MID  estimates
for individual HRQL outcomes. We also improved
on existing methods by ensuring the MID range
included the next score larger than the variability of
the scale and by using the interquartile range to
identify plausible ranges of MIDs. While we illus-
trated this approach with the FACT-BRM in the
context of a clinical trial, it can be easily and suc-
cessfully applied to other HRQL instruments and
research settings.
Source of ﬁnancial support: This research was supported
by Novartis Pharmaceuticals.
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